Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by Enos Bernasconi and Alexandra Calmy.
Enos Bernasconi
Connection Strength
0.814
Alexandra Calmy
  1. Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. BMC Infect Dis. 2019 Oct 10; 19(1):834.
    View in: PubMed
    Score: 0.053
  2. Cost Estimates for Human Immunodeficiency Virus (HIV) Care and Patient Characteristics for Health Resource Use From Linkage of Claims Data With the Swiss HIV Cohort Study. Clin Infect Dis. 2019 02 15; 68(5):827-833.
    View in: PubMed
    Score: 0.051
  3. Inferring the age difference in HIV transmission pairs by applying phylogenetic methods on the HIV transmission network of the Swiss HIV Cohort Study. Virus Evol. 2018 07; 4(2):vey024.
    View in: PubMed
    Score: 0.049
  4. Tracing HIV-1 strains that imprint broadly neutralizing antibody responses. Nature. 2018 09; 561(7723):406-410.
    View in: PubMed
    Score: 0.049
  5. Distinct, IgG1-driven antibody response landscapes demarcate individuals with broadly HIV-1 neutralizing activity. J Exp Med. 2018 06 04; 215(6):1589-1608.
    View in: PubMed
    Score: 0.048
  6. The Cumulative Impact of Harm Reduction on the Swiss HIV Epidemic: Cohort Study, Mathematical Model, and Phylogenetic Analysis. Open Forum Infect Dis. 2018 May; 5(5):ofy078.
    View in: PubMed
    Score: 0.048
  7. Lipodystrophy Increases the Risk of CKD Development in HIV-Positive Patients in Switzerland: The LIPOKID Study. Kidney Int Rep. 2018 Sep; 3(5):1089-1099.
    View in: PubMed
    Score: 0.048
  8. Long-term Immune Response to Yellow Fever Vaccination in Human Immunodeficiency Virus (HIV)-Infected Individuals Depends on HIV RNA Suppression Status: Implications for Vaccination Schedule. Clin Infect Dis. 2018 03 19; 66(7):1099-1108.
    View in: PubMed
    Score: 0.047
  9. Dissecting HIV Virulence: Heritability of Setpoint Viral Load, CD4+ T-Cell Decline, and Per-Parasite Pathogenicity. Mol Biol Evol. 2018 01 01; 35(1):27-37.
    View in: PubMed
    Score: 0.047
  10. Adverse events of raltegravir and dolutegravir. AIDS. 2017 08 24; 31(13):1853-1858.
    View in: PubMed
    Score: 0.046
  11. Rilpivirine use in the Swiss HIV cohort study: a prospective cohort study. BMC Infect Dis. 2017 07 06; 17(1):476.
    View in: PubMed
    Score: 0.045
  12. Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis. 2017 05 01; 64(9):1275-1278.
    View in: PubMed
    Score: 0.045
  13. Human papillomavirus antibody response following HAART initiation among MSM. AIDS. 2017 02 20; 31(4):561-569.
    View in: PubMed
    Score: 0.044
  14. High prevalence of physical inactivity among patients from the Swiss HIV Cohort Study. AIDS Care. 2017 08; 29(8):1056-1061.
    View in: PubMed
    Score: 0.044
  15. Factors associated with syphilis incidence in the HIV-infected in the era of highly active antiretrovirals. Medicine (Baltimore). 2017 Jan; 96(2):e5849.
    View in: PubMed
    Score: 0.044
  16. Ability to Work and Employment Rates in Human Immunodeficiency Virus (HIV)-1-Infected Individuals Receiving Combination Antiretroviral Therapy: The Swiss HIV Cohort Study. Open Forum Infect Dis. 2016 Jan; 3(1):ofw022.
    View in: PubMed
    Score: 0.041
  17. HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. BMC Gastroenterol. 2015 Jul 08; 15:79.
    View in: PubMed
    Score: 0.039
  18. Prevalence of comedications and effect of potential drug-drug interactions in the Swiss HIV Cohort Study. Antivir Ther. 2010; 15(3):413-23.
    View in: PubMed
    Score: 0.027
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.